You're reading a book and the words on the page start to warp and bend. Straight lines look wavy. There's a dark, blurry spot right in the center of your vision — and no matter where you look, it's there. You go to the eye doctor, and the words hit hard: "You have macular degeneration."
Age-related macular degeneration (AMD) is the leading cause of vision loss in Americans over 65, affecting approximately 11 million people. It damages the macula — the small, central part of the retina responsible for sharp, straight-ahead vision needed for reading, driving, and recognizing faces. The "wet" form of AMD, though less common, is responsible for most severe vision loss: abnormal blood vessels grow beneath the retina, leak fluid and blood, and rapidly destroy central vision.
For wet AMD, the standard treatment is regular anti-VEGF injections — medications like aflibercept (Eylea), ranibizumab (Lucentis), and conbercept that are injected directly into the eye to block the growth of leaky blood vessels. These injections work — they can preserve and sometimes improve vision. But they come at a steep cost: each injection runs $2,000 or more in the United States, and patients often need them every month for the first several months, then every one to two months indefinitely. Over just a few years, the total cost can exceed $50,000 per eye — even with insurance, co-pays and coverage gaps can be substantial.
And AMD isn't the only retinal disease threatening vision. Diabetic retinopathy affects approximately 7.7 million Americans with diabetes, and as the disease progresses, it can cause bleeding, scarring, and retinal detachment that requires laser treatment or surgery. Retinal detachment itself — a medical emergency where the retina pulls away from its normal position — affects roughly 30,000 Americans each year and requires prompt surgical repair to prevent permanent blindness.
For all these conditions, the treatment is available. But for many patients, the cost — especially the ongoing cost of anti-VEGF injections — is simply unsustainable.
It's no wonder, then, that a growing number of patients are looking beyond their borders for retinal care. And increasingly, they're discovering that **medical treatment in China** offers advanced retinal surgery and anti-VEGF therapy, experienced vitreoretinal surgeons, and significant cost savings.
When people think about **affordable surgery abroad**, retinal care might not be the first thing that comes to mind. But China has developed world-class vitreoretinal programs — with some of the highest surgical volumes in the world — and international patients are starting to take notice.
**Dramatic cost savings.** This is where the numbers really speak. A loading dose of three anti-VEGF injections for macular degeneration in China costs approximately $1,800 total — compared to $6,000 or more for the same three injections in the United States. For patients needing vitrectomy surgery (for retinal detachment, macular hole, epiretinal membrane, or advanced diabetic retinopathy), costs in China range from $2,800 to $7,000 — compared to $5,000 to $15,000 in the US for a standard vitrectomy, and $20,000 or more for complex retinal detachment repair. Even after factoring in flights, accommodation, and a companion's expenses, the total cost is often dramatically lower than what you'd pay at home — savings of 70 to 75 percent. For patients facing years of ongoing anti-VEGF injections, these savings can be life-changing.
**The same medications, a lower price.** China's leading retinal centers offer the same anti-VEGF medications used in Western centers — including aflibercept, ranibizumab, and conbercept (a Chinese-developed anti-VEGF drug with proven efficacy and a lower price point). Conbercept, in particular, has been widely adopted in China due to its effectiveness and affordability, and it's increasingly recognized in international ophthalmology. The difference isn't the medication — it's the price, driven by China's national volume-based procurement (VBP) reforms that have dramatically reduced the cost of ophthalmic drugs.
**Advanced minimally invasive vitrectomy.** China's leading retinal centers use 25-gauge and 27-gauge micro-incision vitrectomy systems — the smallest, least invasive vitrectomy technology available. These ultra-small incisions (less than half a millimeter) require no stitches, result in less post-operative discomfort and inflammation, and allow for faster visual recovery compared to traditional 20-gauge vitrectomy. Chinese vitreoretinal surgeons have extensive experience with these systems, having performed them on tens of thousands of patients. For patients needing surgery for retinal detachment, macular hole, epiretinal membrane, or diabetic retinopathy, this minimally invasive approach means quicker recovery and better outcomes.
**AI-powered retinal screening.** China is a global leader in applying artificial intelligence to ophthalmology. Leading retinal centers deploy AI fundus screening systems (NMPA-cleared platforms like Airdoc and Vistel) that can analyze retinal photographs in seconds — detecting diabetic retinopathy, macular degeneration, glaucoma, and other conditions with accuracy comparable to human specialists. For international patients, this technology enables rapid, precise screening and diagnosis as part of the pre-operative evaluation — ensuring that treatment plans are based on the most detailed and accurate imaging available.
**The world's highest surgical volume.** In retinal surgery, as in many medical fields, experience matters. China's top eye hospitals — including leading centers in Shanghai, Beijing, and Guangzhou — perform some of the highest volumes of vitreoretinal surgery in the world. Vitreoretinal specialists at these centers handle complex cases routinely: advanced proliferative diabetic retinopathy, complex retinal detachments with proliferative vitreoretinopathy (PVR), myopic traction maculopathy, and recurrent retinal detachments. This extraordinary volume means surgeons have encountered and managed virtually every anatomical variation and complication — developing refined techniques and efficient workflows. For patients, this depth of experience translates into precise, safe surgery and consistent outcomes.
**Comprehensive retinal care.** Beyond anti-VEGF injections and vitrectomy, China's leading retinal centers offer a full spectrum of retinal treatments, including: focal and grid laser photocoagulation for diabetic retinopathy; pneumatic retinopexy for selected retinal detachments; scleral buckling; and treatment for retinal vein occlusion, macular edema, and inherited retinal diseases. This comprehensive capability means patients can receive all their retinal care in one place — rather than coordinating across multiple specialists.
**International standards of care.** Many **Chinese hospitals for international patients** have vitreoretinal departments at Grade 3A hospitals — China's highest hospital classification. These facilities adhere to international infection control protocols (critical for intraocular injections and surgery), use FDA-approved or CE-marked devices and medications, and follow global best practices for retinal care and patient safety. For patients considering eye injections or surgery — where sterile technique and precise surgical skill are critical — these standards provide peace of mind that the care they receive meets the highest global benchmarks.
If you're considering retinal treatment abroad, you probably have questions about the process. How does the evaluation work? What about ongoing injections and follow-up? Is there a language barrier?
- Remote initial consultations based on your existing retinal imaging (OCT, fundus photos, fluorescein angiography)
- Comprehensive pre-operative evaluation, including OCT, fundus autofluorescence, and fluorescein angiography
For patients who want support from the very beginning, services like **CNHealthLink** specialize in connecting international patients with China's leading vitreoretinal centers. From initial case evaluation through treatment and follow-up, these platforms help patients navigate the process of seeking **medical treatment in China** — ensuring they have the information and support they need at every step of their retinal care journey.
Of course, **affordable surgery abroad** and retinal care in China isn't the right choice for everyone. Retinal detachment is a medical emergency that requires prompt local treatment — it's not a condition that can wait for international travel. For patients with wet AMD or diabetic retinopathy requiring ongoing anti-VEGF injections, treatment in China can be an excellent option for loading doses or periodic treatment, but patients should have a plan for ongoing maintenance injections with a local retina specialist at home. And as with any eye procedure, there are potential risks, including infection, bleeding, and cataract progression. Patients should discuss expected outcomes and risks with their retina specialist before proceeding.
But for patients facing the ongoing, expensive burden of anti-VEGF injections for macular degeneration — or those needing vitrectomy surgery for macular hole, epiretinal membrane, or diabetic retinopathy — exploring retinal care in China could be well worth considering. The combination of the same anti-VEGF medications used in Western centers, advanced 25G minimally invasive vitrectomy, AI-powered screening, the world's highest surgical volumes, and dramatic cost savings makes China an increasingly attractive destination for retinal treatment.
If you've been diagnosed with macular degeneration, diabetic retinopathy, or another retinal condition — and you're concerned about the ongoing cost of treatment — know that you have options. Research accredited facilities, compare costs and treatment options, and consider reaching out to a medical advisory service that specializes in international ophthalmic care. They can help you understand whether retinal treatment in China might be right for your specific condition.
Your central vision is precious — and you don't have to choose between preserving it and financial stability. Sometimes, the path to protecting your sight leads further than you think.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making decisions about treatment. Retinal detachment is a medical emergency requiring immediate local care. Treatment outcomes vary by individual and are not guaranteed.